You’ve tried two antidepressants. Maybe three. Each one came with a waiting period, side effects, and eventually the same disappointing result. Now your doctor has mentioned TMS therapy, and for the first time in a while, you feel a flicker of hope. Then the next thought arrives: Will my insurance cover this?
It’s one of the most common questions we hear at Delray Brain Science. And we understand why. Navigating insurance for any treatment is frustrating, but for newer or less familiar therapies, it can feel like decoding a foreign language. The good news is that TMS therapy has come a long way in terms of insurance acceptance. What was once considered an emerging treatment is now recognized by most major insurers as a medically necessary option for the right patients.
We’ve helped many patients in Florida work through the insurance process for TMS, and we want to share what we know. This guide covers how coverage works in 2026, which plans typically cover TMS, what you need to qualify, and exactly what to expect with your out-of-pocket costs. Our goal is to take the guesswork out of this so you can focus on what actually matters: getting better.
Transcranial Magnetic Stimulation, or TMS, is a non-invasive brain stimulation therapy that uses precisely targeted magnetic pulses to activate underactive regions of the brain involved in mood regulation. During a session, a magnetic coil is placed against the scalp and delivers repetitive pulses to the prefrontal cortex, the area most associated with depression. There are no anesthesia requirements, no recovery time, and patients can drive themselves home afterward.
The turning point for insurance coverage came in 2008, when the FDA cleared TMS for treatment-resistant depression using the NeuroStar system. That clearance was significant because it signaled that TMS had moved beyond the experimental stage and into the category of proven, evidence-based treatment. Since then, the FDA has expanded clearance to include obsessive-compulsive disorder in 2018 and smoking cessation in 2020, further establishing TMS as a versatile and credible therapeutic tool.
For insurance companies, FDA clearance is only part of the equation. Insurers also consider clinical evidence, cost-effectiveness, and whether a treatment is medically necessary rather than elective. Over the years, a growing body of peer-reviewed research has demonstrated that TMS produces meaningful improvements in patients who have not responded adequately to antidepressant medications. You can learn more about how TMS works and why it succeeds where traditional medications fall short.
There’s also a practical financial argument. Patients with treatment-resistant depression often cycle through multiple medications over months or years, accumulating costs from prescriptions, office visits, and sometimes hospitalizations. TMS, delivered as a defined course of treatment, can represent a more cost-effective path for both the patient and the insurer when traditional options have failed. Insurers recognized this, and coverage has expanded accordingly.
Today, TMS is covered by most major commercial insurance plans, Medicare, and in some cases Medicaid, when specific clinical criteria are met. The criteria exist to ensure coverage goes to patients for whom TMS is genuinely the appropriate next step, not as a first-line treatment. Understanding those criteria is key to successfully navigating the authorization process.
Florida residents have access to a wide range of insurance plans, and the majority of major commercial carriers now include TMS therapy in their coverage policies for treatment-resistant depression. That said, coverage is never automatic. It depends on your specific plan, your diagnosis, and whether you meet the medical necessity criteria your insurer requires.
Among the commercial carriers we work with regularly, Blue Cross Blue Shield of Florida, Aetna, Cigna, and UnitedHealthcare all have established TMS coverage policies. Humana and Beacon Health Options are others that cover TMS under qualifying circumstances.
Medicare and Medicaid in Florida
Medicare covers TMS therapy at the national level for patients who meet criteria related to treatment-resistant major depressive disorder. Generally, Medicare requires documentation of a formal diagnosis and evidence that the patient has not responded adequately to antidepressant treatment. Coverage is subject to your Medicare plan type, whether you have Original Medicare or a Medicare Advantage plan, and the specific terms of your policy.
Florida Medicaid coverage for TMS is more variable. Florida Medicaid operates largely through managed care organizations, and each plan sets its own coverage policies within state guidelines. Some managed care plans cover TMS, while others do not yet include it. If you’re on a Florida Medicaid managed care plan, we recommend calling your plan directly to ask about TMS coverage and prior authorization requirements.
Your plan type affects both your access to TMS and your cost exposure in meaningful ways. Here’s how the main plan types typically work:
PPO plans generally offer the most flexibility. You can see out-of-network providers, though you’ll pay more to do so. If your preferred TMS clinic is in-network, your costs will be significantly lower.
HMO plans require you to stay within a defined network of providers and often require a referral from your primary care physician before seeing a specialist or accessing a treatment like TMS. Going out of network with an HMO typically means paying the full cost yourself.
EPO plans are a hybrid of sorts. They don’t require referrals like HMOs, but they also don’t cover out-of-network care like PPOs. You must use providers within the plan’s network to receive benefits.
Understanding what insurers want to see before approving TMS is one of the most important pieces of this puzzle. Prior authorization is almost always required, and the approval process depends on how well the clinical documentation aligns with the insurer’s medical necessity criteria.
Most Florida insurers follow a similar framework when evaluating TMS requests. The core requirements typically include the following:
A confirmed diagnosis of major depressive disorder (MDD): Your diagnosis must be formally documented in your medical records.
Evidence of failed antidepressant trials: Most insurers require documentation showing that you have tried at least two adequate antidepressant trials without sufficient improvement. “Adequate” generally means the medication was taken at a therapeutic dose for a sufficient duration, typically several weeks or longer. Some insurers require more than two failed trials, so it’s worth checking your specific policy.
Current depressive symptoms of meaningful severity: Clinical notes documenting your current symptom burden help establish that TMS is clinically appropriate at this time, not simply a preference.
Some plans also require that you have been under the care of a psychiatrist or prescribing clinician rather than having managed your treatment solely through a primary care physician. Advanced diagnostic tools like brain mapping can also help clinicians build a stronger case for medical necessity by providing objective data about brain function.
When we submit a prior authorization request on your behalf, we compile a clinical package that typically includes your psychiatric evaluation, medication history with dates and dosages, clinical notes documenting treatment response and symptom severity, and a letter of medical necessity explaining why TMS is the appropriate next step for you. The strength of this documentation directly affects the likelihood of approval.
Denials are more common when documentation is incomplete or when the insurer’s criteria haven’t been clearly addressed. The most frequent issues we see include insufficient evidence of failed medication trials, missing dosage or duration information for prior medications, and requests submitted without a formal psychiatric diagnosis on record. Starting the process with thorough, organized documentation reduces the chance of an initial denial and makes any appeal much stronger if one becomes necessary.
Even when TMS is covered by your insurance, you’ll likely have some out-of-pocket responsibility. How much depends on your specific plan’s cost-sharing structure and where you are in your deductible for the year.
A standard course of TMS therapy involves approximately 30 to 36 sessions delivered over 6 to 9 weeks. Most sessions are scheduled five days a week and last around 20 to 40 minutes. Because TMS involves multiple visits over an extended period, your cost-sharing structure matters more than it would for a single procedure.
If you haven’t met your annual deductible yet, you may owe the full contracted rate for early sessions until your deductible is satisfied. Once your deductible is met, your plan’s coinsurance kicks in, meaning you pay a percentage of the allowed amount per session and your insurer covers the rest. Some plans use a flat copay per visit instead of coinsurance.
Because TMS involves many sessions, patients who start treatment early in the plan year often meet their deductible partway through the course, which reduces their costs for the remaining sessions. Patients who start treatment later in the year, after already meeting their deductible, may find their out-of-pocket costs lower overall.
Choosing an in-network TMS provider is one of the most significant financial decisions you can make in this process. In-network providers have negotiated rates with your insurer, which lowers both what you owe and what counts toward your out-of-pocket maximum. Out-of-network providers charge higher rates, your insurer may cover a smaller percentage or nothing at all depending on your plan type, and those costs may not count toward your in-network out-of-pocket maximum. The difference can be substantial over a full course of treatment.
For patients with high deductibles or partial coverage, we offer flexible payment plans at Delray Brain Science. We work with patients to find a payment structure that makes treatment accessible. Some patients also explore complementary approaches alongside TMS, such as the RMOKI ketamine treatment protocol, which may offer additional coverage pathways. Some patients also use health savings accounts (HSAs) or flexible spending accounts (FSAs) to cover their share of TMS costs, since TMS qualifies as a medical expense under IRS guidelines. If cost is a concern, we encourage you to ask our team about your options before assuming treatment is out of reach.
Verifying your insurance benefits before your first session is essential. It removes uncertainty, helps you plan financially, and avoids surprises after treatment has already started. Here is a clear process you can follow.
1. Call the member services number on the back of your insurance card and tell the representative you are inquiring about coverage for TMS therapy.
2. Ask specifically about the CPT codes used for TMS billing: 90867 (treatment planning), 90868 (subsequent delivery sessions), and 90869 (motor threshold re-determination). These codes are how TMS is identified in the billing system, and referencing them helps ensure you get accurate information.
3. Ask whether prior authorization is required, what the medical necessity criteria are, and whether your specific plan has a TMS coverage policy.
4. Request written confirmation of your benefits or a reference number for the call so you have documentation of what you were told.
We know that calling your insurance company and navigating benefit questions isn’t something most people want to do on their own, especially when they’re already dealing with depression. That’s why our team at Delray Brain Science handles insurance verification on behalf of our patients at no cost.
A denial is not the end of the road. Florida patients have the right to appeal insurance coverage decisions, and many initial denials are overturned when a well-documented appeal is submitted. The appeals process typically involves submitting a formal written appeal with additional clinical documentation, including detailed treatment history, notes on symptom severity, and a clinical justification for why TMS is medically necessary for you specifically.
Timelines for appeals vary by insurer and plan type, but Florida law requires insurers to respond to standard appeals within a defined timeframe. Patients dealing with cognitive challenges related to their condition may also benefit from brain training for memory and mental clarity while navigating the appeals timeline. Our clinical team can help prepare the documentation needed to support a strong appeal, and we guide patients through this process when it becomes necessary.
If you’ve read this far, you’re probably someone who has been struggling for a while and is genuinely trying to figure out whether TMS is an option for you. We want you to know something: insurance coverage for TMS is more accessible than most people expect, particularly for treatment-resistant depression. The process has real steps, real requirements, and real paperwork, but it is navigable, and you don’t have to navigate it alone.
At Delray Brain Science, we specialize in helping patients who haven’t found relief through traditional approaches. Our team includes experienced clinicians who understand both the clinical and administrative sides of TMS treatment, and we’ve built our process specifically to reduce the burden on patients who are already carrying a lot.
Whether you’re ready to move forward or just starting to explore your options, we invite you to reach out to our team. You can also learn more about our full range of brain health services, including TMS therapy, ketamine treatment, neurofeedback, and psychiatric evaluation. A conversation with us costs nothing, and it might be the step that changes everything.
You’ve already done the hard work of trying to get better. Let us handle the insurance part.
